**Name of Journal:** *World Journal of Biological Chemistry*

**Manuscript NO:** 57814

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Inhibition of matrix metalloproteinase-9 secretion by dimethyl sulfoxide and cyclic adenosine monophosphate in human monocytes**

Denner DR *et al.* Inhibition of MMP-9 secretion

Darcy R Denner, Maria LD Udan-Johns, Michael R Nichols

**Darcy R Denner, Maria LD Udan-Johns, Michael R Nichols,** Department of Chemistry and Biochemistry, University of Missouri-St. Louis, St Louis, MO 63121, United States

**Author contributions:** Nichols MR conceived the ideas and supervised the project; Denner DR and Udan-Johns ML planned and carried out the experiments; Nichols MR wrote the manuscript in consultation with Denner DR and Udan-Johns ML. All authors have read and approve the final manuscript.

**Supported by** the University of Missouri-St. Louis, Alzheimer’s Association, No. NIRG-06-27267; and the Missouri Alzheimer’s and Related Disorders Research Program.

**Corresponding author: Michael R Nichols, PhD, Professor,** Department of Chemistry and Biochemistry, University of Missouri-St. Louis, One University Blvd, St Louis, MO 63121, United States. nicholsmic@umsl.edu

**Received:** June 24, 2020

**Revised:** November 17, 2020

**Accepted:** December 30, 2020

**Published online:** January 27, 2021

**Abstract**

BACKGROUND

Matrix metalloproteinases (MMPs), including MMP-9, are an integral part of the immune response and are upregulated in response to a variety of stimuli. New details continue to emerge concerning the mechanistic and regulatory pathways that mediate MMP-9 secretion. There is significant evidence for regulation of inflammation by dimethyl sulfoxide (DMSO) and 3',5'-cyclic adenosine monophosphate (cAMP), thus investigation of how these two molecules may regulate both MMP-9 and tumor necrosis factor α (TNFα) secretion by human monocytes was of high interest. The hypothesis tested in this study was that DMSO and cAMP regulate MMP-9 and TNFα secretion by distinct mechanisms.

AIM

To investigate the regulation of lipopolysaccharide (LPS)-stimulated MMP-9 and tumor necrosis factor α secretion in THP-1 human monocytes by dimethyl sulfoxide and cAMP.

METHODS

The paper describes a basic research study using THP-1 human monocyte cells. All experiments were conducted at the University of Missouri-St. Louis in the Department of Chemistry and Biochemistry. Human monocyte cells were grown, cultured, and prepared for experiments in the University of Missouri-St. Louis Cell Culture Facility as per accepted guidelines. Cells were treated with LPS for selected exposure times and the conditioned medium was collected for analysis of MMP-9 and TNFα production. Inhibitors including DMSO, cAMP regulators, and anti-TNFα antibody were added to the cells prior to LPS treatment. MMP-9 secretion was analyzed by gel electrophoresis/western blot and quantitated by ImageJ software. TNFα secretion was analyzed by enzyme-linked immuno sorbent assay. All data is presented as the average and standard error for at least 3 trials. Statistical analysis was done using a two-tailed paired Student *t*-test. *P* values less than 0.05 were considered significant and designated as such with an asterisk in the Figures (*P* < 0.05). LPS and cAMP regulators were from Sigma-Aldrich, MMP-9 standard and antibody and TNFα antibodies were from R&D Systems, and amyloid-β peptide was from rPeptide.

RESULTS

In our investigation of MMP-9 secretion from THP-1 human monocytes, we made the following findings. Inclusion of DMSO in the cell treatment inhibited LPS-induced MMP-9, but not TNFα, secretion. Inclusion of DMSO in the cell treatment at different concentrations inhibited LPS-induced MMP-9 secretion in a dose-dependent fashion. A cell-permeable cAMP analog, dibutyryl cAMP, inhibited both LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells with the adenylyl cyclase activator forskolin inhibited LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells with the general cAMP phosphodiesterase inhibitor IBMX reduced LPS-induced MMP-9 and TNFα in a dose-dependent fashion. Pre-treatment of monocytes with an anti-TNFα antibody blocked LPS-induced MMP-9 and TNFα secretion. Amyloid-β peptide induced MMP-9 secretion and occurred much later than TNFα secretion. The latter two findings strongly suggested an upstream role for TNFα in mediating LPS-stimulate MMP-9 secretion.

CONCLUSION

The cumulative data indicated that MMP-9 secretion was a distinct process from TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα, suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell exposure time points. The pattern of cAMP inhibition for these two molecules suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key component of the pathway leading to MMP-9 secretion. This temporal relationship fit a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link between TNFα secretion and MMP-9 secretion.

**Key Words:** Matrix metalloproteinase-9; Inflammation; Human monocytes; Tumor necrosis factor alpha; Cyclic adenosine monophosphate; Dimethyl sulfoxide

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Denner DR, Udan-Johns ML, Nichols MR. Inhibition of matrix metalloproteinase-9 secretion by dimethyl sulfoxide and cyclic adenosine monophosphate in human monocytes. *World J Biol Chem* 2021; 12(1): 1-14

**URL:** https://www.wjgnet.com/1949-8454/full/v12/i1/1.htm

**DOI:** https://dx.doi.org/10.4331/wjbc.v12.i1.1

**Core Tip:** This article describes the stimulation of matrix metalloproteinase-9 (MMP-9) and tumor necrosis factor α (TNFα) secretion from human monocyte cells by lipopolysaccharide, and the inhibition of this process by dimethyl sulfoxide and increased intracellular levels of 3',5'-cyclic adenosine monophosphate. The experimental findings demonstrated that dimethyl sulfoxide concentration must be carefully controlled in inflammatory studies, that MMP-9 secretion occurred downstream from TNFα secretion and that the two processes were distinct, and that TNFα is an integral component of the pathway leading to MMP-9 secretion.

**INTRODUCTION**

Matrix-metalloproteinases (MMPs) are zinc-dependent extracellular matrix-degrading enzymes that have a key role in a wide variety of physiological[1] and pathological[2,3] processes. Physiological processes include embryonic development, morphogenesis, angiogenesis, tissue repair, and immune responses while pathological processes include arthritis, cancer, neurological disease, breakdown of the blood–brain barrier, and cerebral hemorrhage. MMP subgroups are comprised of collagenases, gelatinases, stromalysins, and membrane-type and their activity is controlled by gene expression, zymogen activation, and endogenous tissue inhibitors[4,5]. MMP-1, MMP-8, MMP-13, and MMP-18 are collagenases that cleave interstitial collagen type I, II, and III and digest some extracellular matrix and non- extracellular matrix proteins. MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are gelatinases that degrade both collagens and gelatins[3].

MMPs have been described as a type of inflammatory cytokine since they are significantly expressed, secreted, and activated upon stimulation of inflammatory cells by various endogenous or exogenous factors[2]. MMP-9 is an important MMP in myeloid/monocyte cells and substantial work has been done on understanding the types of stimuli and mechanistic pathways that lead to MMP-9 secretion. Stimulation of inflammatory cells with lipopolysaccharide (LPS), cytokines, amino acids, and protein aggregates such as amyloid-β (Aβ) triggers signaling pathways that involve nuclear factor κB, protein kinase Cα, extracellular signal-regulated kinase 1 and 2 and mitogen-activated kinase p38, and lead to MMP-9 secretion[6-9]. MMP-9 secretion, and inflammation in general, can be regulated in a number of ways and there have been previous reports of regulation by both dimethyl sulfoxide (DMSO)[9-11] and the intracellular signaling molecule 3',5'-cyclic adenosine monophosphate (cAMP)[7].

DMSO is commonly used as a vehicle for delivering hydrophobic compounds, such as enzyme inhibitors or signaling regulators to cells, thus its role as an inflammatory regulator is of significant interest. DMSO inhibited production of MMP-9 in TNFα-stimulated human keratinocytes at concentrations of 0.75% and higher[9]. DMSO also decreased interleukin-1β (IL-1β)-induced interleukin-6 and macrophage chemoattractant protein-1 secretions in a dose-dependent manner in differentiated-Caco-2 cells[10]. Suppression of many pro-inflammatory cytokines/chemokines by DMSO in *Escherichia coli*- and herpes simplex virus-1-stimulated whole human blood has also been demonstrated[11]. Cyclic AMP is a critical signaling molecule and is involved in a myriad of physiological cellular processes including regulation of inflammatory processes. Support for this regulation includes the observation that adenosine dose-dependently decreased MMP-9 secretion in isolated human neutrophils regardless of whether the cells were stimulated by *N*-formylmethionyl-leucyl-phenylalanine, LPS, or H2O2[7]. Adenosine increased intracellular cAMP levels and it was concluded that the effect was mediated through a cAMP-mediated pathway[7].

MMP-9 and TNFα are important markers and mediators of inflammatory processes in immune cells. In this report we sought to further examine temporal and regulatory mechanisms of MMP-9 secretion in THP-1 human monocytes after stimulation with LPS. Specifically, dose-dependent regulation of MMP-9 and TNFα by the aprotic solvent DMSO and the intracellular signaling molecule cAMP. The findings demonstrated distinct regulatory effects by DMSO and cAMP on MMP-9 and TNFα secretion. These distinct, but significant and efficacious, effects by DMSO and cAMP revealed a probable role for TNFα in the pathway leading to MMP-9 secretion.

**MATERIALS AND METHODS**

***Cellular assays***

THP-1 monocytic cells were obtained from ATCC (Manassas, VA, United States) and maintained in RPMI-1640 culture medium (HyClone, Logan, UT, United States) containing 2 mmol/L L-glutamine, 25 mmol/L HEPES, 1.5 g/L sodium bicarbonate, 10% fetal bovine serum (HyClone), 50 U/mL penicillin, 50 mg/mL streptomycin (HyClone), and 50 mmol/L b-mercaptoethanol at 37 °C in 5% CO2. For cell assays, THP-1 cells were centrifuged at 500 g for 10 min, washed, and resuspended in reduced fetal calf serum (2%) growth medium. Cell concentrations were adjusted to 1.0 × 106 cells/mL and 0.3 mL (3.0 × 105 cells) was added to individual wells of a 48-well sterile culture plate. For experiments evaluating the regulatory effect of DMSO on LPS-stimulated MMP-9 and TNFα secretion, suspension THP-1 monocyte cells were treated with DMSO (Thermo Fisher Scientific) at concentrations ranging from 0.016%-2% for 5 min prior to subsequent treatment with 1 μg/mL *Escherichia coli* bacterial 026.B6 LPS (Sigma-Aldrich, St. Louis). Cells were incubated for 72 h at 37 °C in 5% CO2. DMSO concentrations were varied from 0.016%-2% to evaluate the effect on cell response and specific concentrations for each experiment is detailed in each figure legend. Control cell treatments without LPS but in the presence of DMSO were done for all studies. For experiments assessing the regulatory role of cAMP on LPS-stimulated MMP-9 and TNFα secretion, THP-1 monocytes were treated with cAMP regulators dibutyryl 3',5'-cyclic adenosine monophosphate (Bt2-cAMP), forskolin (Fsk), and 3-isobutyl-1-methylxanthine (IBMX) for 5 min prior to subsequent treatment with 1 μg/mL LPS. Cells were incubated for 6-72 h at 37 °C in 5% CO2. In one experiment, cells were stimulated with 0.3 μg/mL LPS. Concentrations or concentration ranges used for the regulators were 0.3 mmol/L for Bt2-cAMP, 0.01-0.1 mmol/L for Fsk, and 0.01-0.3 mmol/L for IBMX. Control cell treatments without LPS but in the presence of cAMP regulators were done for all studies. For experiments assessing the effect of an anti-human TNFα monoclonal antibody (MAB610, R&D Systems, Minneapolis, MN, United States) on LPS-stimulated MMP-9 and TNFα secretion, THP-1 monocytes were treated with the antibody for 5 min prior to subsequent treatment with 1 μg/mL LPS. Cells were incubated for 48 h at 37 °C in 5% CO2. Control cell treatments with or without LPS and/or in the presence or absence of the antibody, were done for these studies. After all treatments, cells were removed from each well, centrifuged at 2500 g for 10 min, and the supernatant was collected and frozen at −20 °C for subsequent analysis.

***Western blot***

Supernatants from individual wells of treated THP-1 monocytes were mixed 1:1 with Laemmli SDS sample buffer (Bio-Rad) containing 5% β-mercaptoethanol. Samples and 10 μL recombinant human MMP-9 western blotting standard (WBC018, R&D Systems, Minneapolis, MN, United States) were heated at 95 °C for 5 min and separated on 7.5% Tris-HCl gels (Ready Gel, Bio-Rad) under denaturing conditions (25 mmol/L Tris, 192 mmol/L glycine, 0.1% SDS at pH 8.3) using a Mini Protean 3 Cell (Bio-Rad). Pre-stained SDS-PAGE standards (BioRad) were loaded directly into gel wells. Gels were transferred to Immobilon-P PVDF membrane (Millipore) in transfer buffer containing 25 mmol/L Tris base, 192 mmol/L glycine, and 10% methanol at pH 8.3 using a Tank VEP-2 electroblotting system (Owl Separation Systems). Following protein transfer, the membrane was blocked for 1 h at 25 °C with PBS containing 0.2% Tween 20 (PBST) supplemented with 5% nonfat dry milk, and probed for 1 h at 25 °C with 1 μg/mL goat anti-human MMP-9 antibody (AB911, R&D Systems) in PBST containing 1% milk. After washing membrane 3× in PBST, the membrane was incubated with a 1:1000 dilution of goat anti-mouse IgG-HRP secondary antibody (R&D systems) in PBST containing 1% milk for 1 h at 25 °C. Protein detection was accomplished using ECL Western Blotting Substrate reagents (Pierce) and exposure to film (Kodak). Densitometry of immunoblot TIFF images was done using ImageJ 1.52a.

***Enzyme-linked immuno sorbent assay***

Measurement of secreted TNFα in the supernatants was determined by enzyme-linked immuno sorbent assay (ELISA). Briefly, 100 mL of 4 mg/mL monoclonal anti-human TNFα capture antibody (MAB610, R&D Systems) was added to 96-well plates for overnight incubation at room temperature. Wells were washed with PBS (HyClone) containing 0.05% Tween-20 and blocked with 300 mL PBS containing 1% bull serum albumin (BSA), 5% sucrose and 0.05% NaN3 for 1 h at room temperature. After washing, successive additions of 50 mL samples or standards (2 h), 100 mL biotinylated polyclonal anti-human TNFα detection antibody (BAF210, R&D Systems) in 20 mmol/L Tris with 150 mmol/L NaCl and 0.1% BSA (2 h), 100 mL streptavidin-HRP (R&D Systems) diluted 200 times with PBS containing 1% BSA (20 min), and 100 mL of equal volumes of 3,3',5,5'-tetramethylbenzidine and hydrogen peroxide (KPL, Gaithersburg, MD, United States) (30 min). The reaction was stopped by the addition of 1% H2SO4 solution. The optical density of each sample was analyzed at 450 nm with a reference reading at 630 nm using a SpectraMax 340 absorbance platereader (Molecular Devices, Union City, CA, United States). A standard curve was constructed by sequential dilution of a TNFα standard from 2000-15 pg/mL. The concentration of TNFα in the experimental samples was calculated from a TNFα standard curve of 15-2000 pg/mL.

***Preparation of Aβ***

Amyloid-β peptide (Aβ42) (rPeptide, Bogarth, GA, United States) was dissolved in 100% hexafluoroisopropanol (Sigma) for 1 h, aliquotted into sterile microcentrifuge tubes, dried in a vacuum centrifuge, and stored at -20 °C. Prior to cell treatment the lyophilized peptides were resuspended in sterile water to 100 μmol/L peptide concentration and incubated at 4 °C for 24 h. Cells were exposed to a final concentration of 17 μmol/L Aβ42 for selected times. For experiments conducted on Aβ42-stimulated MMP-9 and TNFα secretion, THP-1 monocytes were treated with Aβ42 at a final concentration of 17 μmol/L, and incubated for 6, 24, or 48 h at 37 °C in 5% CO2. Control cell treatments without Aβ42 were done with the same volume of sterile water.

***Statistical analysis***

Two-tailed paired Student *t*-tests were performed for experiments when applicable to determine the confidence limit at which two measurements were statistically different. Analysis was applied to each data set and *P* values less than 0.05 were considered significant and are designated a in the Figures with a superscript a (a) for (*P* < 0.05) or superscript b (b) for (*P* < 0.01).

**RESULTS**

In the course of investigating MMP-9 secretion by THP-1 human monocytes after exposure to LPS, it was observed that DMSO had an inhibitory effect on this process. Western blot analysis showed that MMP-9 secretion was sensitive to LPS concentration in that 1 μg/mL LPS triggered greater MMP-9 protein secretion compared to 0.1 μg/mL LPS (Figure 1A). The inclusion of 2% DMSO almost completely abolished the release of MMP-9 from THP-1 cells after stimulation with LPS at either concentration (Figure 1A). Densitometry analysis of the immunoblot is provided in Figure 1B. TNFα is a classical proinflammatory cytokine and LPS-induced TNFα secretion in immune cells has been well-studied. Surprisingly, this process was not inhibited by DMSO. The same samples in Figure 1A were analyzed for TNFα levels by ELISA. As expected, 1 μg/mL LPS triggered greater TNFα secretion compared to 0.1 μg/mL in THP-1 cells (Figure 1C). 2% DMSO did not diminish the LPS-induced TNFα response indicating a MMP-9-selective effect by DMSO.

The observation that DMSO inhibited MMP-9 secretion in THP-1 monocytes prompted additional investigation of concentration dependence. THP-1 cells were exposed to increasing concentrations of DMSO prior to stimulation with μg/mL LPS. MMP-9 secretion, measured by immunoblot, was slightly diminished at 0.2% DMSO and almost completely inhibited at 1% DMSO (Figure 2A). Densitometry analysis of the Figure 2A immunoblot allowed non-linear curve fitting of the dose-dependent DMSO effect on secreted MMP-9. The inhibition curve fit yielded an IC50 value of 0.64% DMSO (Figure 2B). Analysis of the same LPS/DMSO samples for TNFα levels again showed no inhibitory effect of DMSO on LPS-stimulated TNFα secretion (Figure 2C).

Bt2-cAMP, a cell-permeable cAMP analog that mimics the activity of cAMP[12], to THP-1 monocytes prior to LPS treatment resulted in an inhibition of MMP-9 secretion (40%), but only at the later cell-exposure time points (Figure 3A and B). The effect of Bt2-cAMP on TNFα was very different in that TNFα secretion was significantly inhibited (> 77%) at earlier and later time points. Fsk, an adenylyl cyclase activator that can also raise intracellular cAMP levels[13], was tested for its ability to alter LPS-induced MMP-9 and TNFα secretion. Due to the hydrophobic nature of Fsk, DMSO was used as a vehicle for a 72 h LPS cell treatment in the current studies. The DMSO concentration was carefully determined and controlled to fully ascertain the effect of Fsk. DMSO did not inhibit LPS-induced MMP-9 secretion at 0.016% and 0.048%, but 0.16% DMSO did inhibit 50% of the control LPS monocyte treatment (Figure 4A and B). Fsk potently inhibited MMP-9 secretion far in excess of any DMSO inhibition that was observed at 30 μmol/L and 100 μmol/L, but not 10 μmol/L, Fsk (Figure 4A and B). As in the earlier data, DMSO did not inhibit LPS-induced TNFα secretion (Figure 4C). However, Fsk dose-dependently inhibited TNFα secretion, with 39% inhibition at 10 μmol/L, 54% inhibition at 30 μmol/L, and 66% inhibition at 100 μmol/L (Figure 4C). The Fsk inhibition values were determined relative to the concomitant DMSO-treated THP-1 monocytes. Fsk also inhibited LPS-induced TNFα secretion at an early time point (6 h), with 57% and 47% inhibition observed at 30 μmol/L and 100 μmol/L respectively (data not shown).

In order to increase intracellular cAMP levels by a different pathway, the cell-permeable general cAMP phosphodiesterase (PDE) inhibitor IBMX was tested. Treatment of THP-1 monocytes with a concentration range of IBMX prior to application of LPS produced a dose-dependent inhibition of MMP-9 secretion (Figure 5A). Quantitation of the immunoblot by densitometry yielded an inhibition plot that was then analyzed by nonlinear curve fitting. The fit produced an IC50 value of 0.05 mmol/L for IBMX inhibition of MMP-9 secretion (Figure 5B, circles). The effect of IBMX on TNFα secretion was also assessed in the same supernatant samples by ELISA. A very similar dose-dependent inhibition was observed for TNFα as for MMP-9 with an IC50 value of 0.08 mmol/L (Figure 5B, diamonds). The temporal and connected relationship between LPS-induced secretion of TNFα and MMP-9 strongly suggested that TNFα played a contributory role in MMP-9 secretion. This idea was tested by the inclusion of an anti-TNFα antibody prior to LPS treatment of THP-1 monocytes. The presence of the TNFα antibody reduced the secretion of MMP-9 when analyzed by immunoblot (Figure 6A). Quantitative analysis by densitometry showed 47% inhibition of MMP-9 by blocking TNFα (Figure 6B, left plot). As expected, the presence of the TNFα antibody significantly reduced TNFα levels in the cell supernatant (Figure 6B, right plot).

In an effort to examine MMP and TNFα secretion by a cell-stimulator other than LPS, the ability of Aβ42 oligomers to trigger THP-1 monocyte MMP-9 secretion was examined. Hexafluoroisopropanol-treated and vacuum-dried Aβ42 was reconstituted in sterile H2O and incubated for 24 h at 4 °C to allow oligomer formation. THP-1 cells exposed to the Aβ42 oligomers began to secrete MMP-9 at 24 h of treatment, with a much larger level by 48 h (Figure 7A). Comparison of the immunoblot densitometry quantitation and ELISA measurement of secreted TNFα indicated that maximum TNFα secretion occurred prior to MMP-9 secretion (Figure 7B). The temporal relationship between to Aβ42 oligomer-induced TNFα secretion and MMP-9 secretion was similar to that observed by LPS. Significant analysis was performed to rule out any LPS contamination within the Aβ42 samples and delineate differences between LPS and Aβ42 stimulation of monocytes. These analytical measures were described in a previous publication[14]. The two pathogens, one exogenous (LPS) and one endogenous (Aβ), both trigger pathways leading to MMP-9 secretion.

**DISCUSSION**

LPS triggers Toll-like receptor 4 (TLR4) activation and downstream signaling pathways that include myeloid differentiation protein 88 and NF-kB-mediated transcription and expression of innate immune genes such as TNFα and IL-1β[15-17]. LPS also activates extracellular signal-regulated kinases 1/2, mitogen-activated kinase p38, mitochondrial reactive oxygen species, and MMP-9 expression[6,18].

DMSO has long been recognized to have anti-inflammatory and analgesic properties[19]. Although controversial, it has been used in a variety of formulations for the treatment of interstitial cystitis, cutaneous scleroderma, and wound healing, with an additional potential as an anti-viral[19]. Furthermore, as a polar, aprotic solvent miscible with water, DMSO is widely used as a vehicle for hydrophobic compounds in cellular assays. Here we show that application of low concentrations (0.2%-0.8%) of DMSO to human monocytes inhibited the secretion of MMP-9. The mechanism by which the inhibition occurred was not a generalized process as DMSO did not inhibit secretion of TNFα, another inflammatory product and mediator. Cyclic AMP, on the other hand, inhibited both TNFα and MMP-9 secretion. The manner in which cAMP was generated in the monocytes did not influence the inhibitory outcome, whether by direct application of a cell-permeable cAMP analog, cAMP synthesis by activation of adenylyl cyclase, or boosting cAMP levels by inhibition of PDE.

Our findings indicated that DMSO concentration should be restricted to 0.4% or below to avoid inadvertent inhibition of MMP-9 secretion. Furthermore, there are specific distinctions in the mechanistic pathways by which MMP-9 and TNFα are secreted, and the inhibitory effect of DMSO on MMP-9 secretion reveals one or more areas of these mechanistic distinctions. Our DMSO inhibitory observations and effective concentration were consistent with other studies. Majtan and Majtan[9] previously demonstrated DMSO inhibition of MMP-9 transcription and synthesis in TNFα-treated human keratinocytes[9]. We expanded our investigation by stimulating monocytes further upstream with LPS and comparing both DMSO and cAMP regulation of TNFα and MMP-9 secretion. The findings showed that DMSO did not alter LPS-induced TNFα levels indicating a distinctive effect for MMP-9. Previous studies have shown DMSO inhibition of MMP-2 in human aorta endothelial cells at slightly higher concentrations of 1%-3%[20]. For other inflammatory molecules, Elisia *et al*[11] found that 0.5%-2% DMSO inhibited expression of numerous cytokines in bacterial-stimulated whole blood samples and in the joints of arthritic mice[11]. The findings on TNFα were mixed, with some inhibition observed at 2% DMSO in whole blood, but no inhibition in the arthritic mouse paws. Hollebeeck *et al*[10] reported DMSO inhibition of the intestinal Caco-2 cell inflammatory response in the range of 0.1%-0.5%. The cells were stimulated with IL-1β or a pro-inflammatory cocktail consisting of IL-1β, TNFα, interferon-γ and LPS. Differential effects by DMSO were observed, whereby DMSO inhibited transcription of IL-6, IL-1α, IL-1β, and cyclooxygenase-2, but not IL-8 or TNFα.

Cyclic-AMP is a ubiquitous second messenger molecule that can modulate a number of processes by direct binding to molecular targets or by activation of cAMP-dependent protein kinase (PKA) and subsequent downstream phosphorylation. Adenylyl cyclase and PDE tightly control cAMP levels by regulating synthesis and degradation respectively. Cyclic AMP is well-recognized as an inflammation modifier in a variety of cell types and an important therapeutic target reviewed in[21,22]. Attenuation of LPS-induced TNFα production by agents that raise cAMP levels was specifically demonstrated in monocyte/macrophage cells[15,23]. Furthermore, elevation of cAMP levels in neutrophils inhibited MMP-9 secretion and implicated cAMP-dependent PKA in the process[7].

The mechanism by which cAMP regulates cytokine pathways has been widely researched and there are multiple points at which this occurs. Two of these areas in monocytes/macrophages include the orphan nuclear receptor Nr4a1 (Nur77) and the nuclear factor κB transcriptional complex. Elevated cAMP levels induce Nur77 expression leading to repression of numerous inflammatory genes reviewed in[24]. Either incomplete or excessive phosphorylation of cAMP response element binding protein can suppress TNFα transcription[25]. PKA can also regulate cAMP response element binding protein/deoxyribonucleic acid binding in ganglioside and plasminogen-induced microglial cytokine production[26]. It has been proposed for some time that cAMP has a role as an inflammation gate-keeper[23]. Our results were consistent with previous findings and showed that increased cAMP levels attenuated LPS-induced MMP-9 and TNFα secretion.

Several aspects of our data indicated that MMP-9 secretion was a distinct process from TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα, suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell exposure time points. The pattern of cAMP inhibition for these two molecules suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key component of the pathway leading to MMP-9 secretion. This temporal relationship fit a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link between TNFα secretion and MMP-9 secretion.

Bacterial LPS stimulation of human monocytic cells has been well-studied and evokes a classical innate immune response to exogenous pathogens *via* TLR4. It is now widely-recognized that endogenous pathogens, such as Aβ in Alzheimer’s disease, can trigger similar pathways *via* TLR4 and other TLRs[14,27-29]. Stimulation of MMP-9 secretion by Aβ42 has been shown previously in THP-1 monocytes[30], murine microglia[31], rat astrocytes[32], and human retinal pigment epithelial cells[33]. Furthermore, MMP-9 levels are significantly elevated in plasma from Alzheimer’s disease patients[34] and in 5xFAD/MBP−/− transgenic mice[35]. Our findings show that Aβ42 oligomer-induced MMP-9 secretion appears to follow the same temporal pathway as LPS in that significant MMP-9 levels were not observed until later cell exposure time points and well after TNFα release. The LPS and Aβ42 results fit a mechanism whereby induced TNFα secretion and subsequent autocrine stimulation of TNF receptor type 1 leads to MMP-9 production and secretion[36].

**CONCLUSION**

The cumulative data indicated that MMP-9 secretion was a distinct process from TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα, suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell exposure time points. The pattern of cAMP inhibition for these two molecules suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key component of the pathway leading to MMP-9 secretion. This temporal relationship fit a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link between TNFα secretion and MMP-9 secretion.

**ARTICLE HIGHLIGHTS**

***Research background***

Matrix metalloproteinases (MMPs), including MMP-9, are an integral part of the immune response and are upregulated in response to a variety of stimuli. New details continue to emerge concerning the mechanistic and regulatory pathways that mediate MMP-9 secretion. There is significant evidence for regulation of inflammation by dimethyl sulfoxide (DMSO) and 3',5'-cyclic adenosine monophosphate (cAMP), thus investigation of how these two molecules may regulate both MMP-9 and tumor necrosis factor α (TNFα) secretion by human monocytes was of high interest. The hypothesis tested in this study was that DMSO and cAMP regulate MMP-9 and TNFα secretion by distinct mechanisms.

***Research motivation***

The objective of this study was further examine temporal and regulatory mechanisms of MMP-9 secretion in THP-1 human monocytes after stimulation with lipopolysaccharide (LPS). Specifically, dose-dependent regulation of MMP-9 and TNFα by the aprotic solvent DMSO and the intracellular signaling molecule cAMP.

***Research objectives***

The objective of this study was further examine temporal and regulatory mechanisms of MMP-9 secretion in THP-1 human monocytes after stimulation with LPS. Specifically, dose-dependent regulation of MMP-9 and TNFα by the aprotic solvent DMSO and the intracellular signaling molecule cAMP.

***Research methods***

The paper describes a basic research study using THP-1 human monocyte cells. All experiments were conducted at the University of Missouri-St. Louis in the Department of Chemistry and Biochemistry. Human monocyte cells were grown, cultured, and prepared for experiments in the University of Missouri-St. Louis Cell Culture Facility as per accepted guidelines. Cells were treated with LPS for selected exposure times and the conditioned medium was collected for analysis of MMP-9 and TNFα production. Inhibitors including DMSO, cAMP regulators, and anti-TNFα antibody were added to the cells prior to LPS treatment. MMP-9 secretion was analyzed by gel electrophoresis/western blot and quantitated by ImageJ software. TNFα secretion was analyzed by enzyme-linked immuno sorbent assay. All data is presented as the average and standard error for at least 3 trials. Statistical analysis was done using a two-tailed paired Student *t*-test *p* values less than 0.05 were considered significant and designated as such with an asterisk in the figures (*P* < 0.05). LPS and cAMP regulators were from Sigma-Aldrich, MMP-9 standard and antibody and TNFα antibodies were from R&D Systems, and amyloid-β peptide was from rPeptide.

***Research results***

In our investigation of MMP-9 secretion from THP-1 human monocytes, we made the following findings. Inclusion of DMSO in the cell treatment inhibited LPS-induced MMP-9, but not TNFα, secretion. Inclusion of DMSO in the cell treatment at different concentrations inhibited LPS-induced MMP-9 secretion in a dose-dependent fashion. A cell-permeable cAMP analog, dibutyryl cAMP, inhibited both LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells with the adenylyl cyclase activator forskolin inhibited LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells with the general cAMP phosphodiesterase inhibitor reduced LPS-induced MMP-9 and TNFα in a dose-dependent fashion. Pre-treatment of monocytes with an anti-TNFα antibody blocked LPS-induced MMP-9 and TNFα secretion. Amyloid-β peptide-induced MMP-9 secretion and occurred much later than TNFα secretion. The latter two findings strongly suggested an upstream role for TNFα in mediating LPS-stimulate MMP-9 secretion.

***Research conclusions***

The cumulative data indicated that MMP-9 secretion was a distinct process from TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα, suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell exposure time points. The pattern of cAMP inhibition for these two molecules suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key component of the pathway leading to MMP-9 secretion. This temporal relationship fit a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link between TNFα secretion and MMP-9 secretion.

***Research perspectives***

Regulation of MMP-9 is a significant important in many disease processes including arthritis and Alzheimer’s disease. Further understanding of the pathways leading to MMP-9 secretion and regulation of this process will be important for managing human health.

**REFERENCES**

1 **Klein T**, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. *Amino Acids* 2011; **41**: 271-290 [PMID: 20640864 DOI: 10.1007/s00726-010-0689-x]

2 **Chen Q**, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. *Mediators Inflamm* 2013; **2013**: 928315 [PMID: 23840100 DOI: 10.1155/2013/928315]

3 **Zipfel P**, Rochais C, Baranger K, Rivera S, Dallemagne P. Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges. *J Med Chem* 2020; **63**: 10705-10725 [PMID: 32459966 DOI: 10.1021/acs.jmedchem.0c00352]

4 **Laronha H**, Caldeira J. Structure and Function of Human Matrix Metalloproteinases. *Cells* 2020; **9** [PMID: 32357580 DOI: 10.3390/cells9051076]

5 **Raeeszadeh-Sarmazdeh M**, Do LD, Hritz BG. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. *Cells* 2020; **9** [PMID: 32466129 DOI: 10.3390/cells9051313]

6 **Lai WC**, Zhou M, Shankavaram U, Peng G, Wahl LM. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. *J Immunol* 2003; **170**: 6244-6249 [PMID: 12794156 DOI: 10.4049/jimmunol.170.12.6244]

7 **Ernens I**, Rouy D, Velot E, Devaux Y, Wagner DR. Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: implication of A2a receptor and cAMP/PKA/Ca2+ pathway. *Circ Res* 2006; **99**: 590-597 [PMID: 16917093 DOI: 10.1161/01.RES.0000241428.82502.d4]

8 **Shin Y**, Yoon SH, Choe EY, Cho SH, Woo CH, Rho JY, Kim JH. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. *Exp Mol Med* 2007; **39**: 97-105 [PMID: 17334233 DOI: 10.1038/emm.2007.11]

9 **Majtan J**, Majtan V. Dimethyl sulfoxide attenuates TNF-α-induced production of MMP-9 in human keratinocytes. *J Toxicol Environ Health A* 2011; **74**: 1319-1322 [PMID: 21899405 DOI: 10.1080/15287394.2011.600661]

10 **Hollebeeck S**, Raas T, Piront N, Schneider YJ, Toussaint O, Larondelle Y, During A. Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the *in vitro* intestinal Caco-2 cell model. *Toxicol Lett* 2011; **206**: 268-275 [PMID: 21878375 DOI: 10.1016/j.toxlet.2011.08.010]

11 **Elisia I**, Nakamura H, Lam V, Hofs E, Cederberg R, Cait J, Hughes MR, Lee L, Jia W, Adomat HH, Guns ES, McNagny KM, Samudio I, Krystal G. DMSO Represses Inflammatory Cytokine Production from Human Blood Cells and Reduces Autoimmune Arthritis. *PLoS One* 2016; **11**: e0152538 [PMID: 27031833 DOI: 10.1371/journal.pone.0152538]

12 **Kaukel E**, Hilz H. Permeation of dibutyryl cAMP into HeLa cells and its convesion to monobutyryl cAMP. *Biochem Biophys Res Commun* 1972; **46**: 1011-1018 [PMID: 4333411 DOI: 10.1016/s0006-291x(72)80242-0]

13 **Peters JR**, Nambi P, Sibley DR, Lefkowitz RJ. Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists. *Eur J Pharmacol* 1984; **107**: 43-52 [PMID: 6151904 DOI: 10.1016/0014-2999(84)90089-x]

14 **Udan ML**, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. *J Neurochem* 2008; **104**: 524-533 [PMID: 17986235 DOI: 10.1111/j.1471-4159.2007.05001.x]

15 **Ollivier V**, Parry GC, Cobb RR, de Prost D, Mackman N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. *J Biol Chem* 1996; **271**: 20828-20835 [PMID: 8702838 DOI: 10.1074/jbc.271.34.20828]

16 **Kielian T**. Toll-like receptors in central nervous system glial inflammation and homeostasis. *J Neurosci Res* 2006; **83**: 711-730 [PMID: 16541438 DOI: 10.1002/jnr.20767]

17 **Hanamsagar R**, Hanke ML, Kielian T. Toll-like receptor (TLR) and inflammasome actions in the central nervous system. *Trends Immunol* 2012; **33**: 333-342 [PMID: 22521509 DOI: 10.1016/j.it.2012.03.001]

18 **Woo CH**, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9 expression *via* a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. *J Immunol* 2004; **173**: 6973-6980 [PMID: 15557194 DOI: 10.4049/jimmunol.173.11.6973]

19 **Capriotti K**, Capriotti JA. Dimethyl sulfoxide: history, chemistry, and clinical utility in dermatology. *J Clin Aesthet Dermatol* 2012; **5**: 24-26 [PMID: 23050031]

20 **Koizumi K**, Tsutsumi Y, Yoshioka Y, Watanabe M, Okamoto T, Mukai Y, Nakagawa S, Mayumi T. Anti-angiogenic effects of dimethyl sulfoxide on endothelial cells. *Biol Pharm Bull* 2003; **26**: 1295-1298 [PMID: 12951474 DOI: 10.1248/bpb.26.1295]

21 **Raker VK**, Becker C, Steinbrink K. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. *Front Immunol* 2016; **7**: 123 [PMID: 27065076 DOI: 10.3389/fimmu.2016.00123]

22 **Pearse DD**, Hughes ZA. PDE4B as a microglia target to reduce neuroinflammation. *Glia* 2016; **64**: 1698-1709 [PMID: 27038323 DOI: 10.1002/glia.22986]

23 **Jin SL**, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. *Proc Natl Acad Sci* 2002; **99**: 7628-7633 [PMID: 12032334 DOI: 10.1073/pnas.122041599]

24 **Maxwell MA**, Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. *Nucl Recept Signal* 2006; **4**: e002 [PMID: 16604165 DOI: 10.1621/nrs.04002]

25 **Chong YH**, Shin YJ, Suh YH. Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. *Mol Pharmacol* 2003; **63**: 690-698 [PMID: 12606779 DOI: 10.1124/mol.63.3.690]

26 **Min KJ**, Yang MS, Jou I, Joe EH. Protein kinase A mediates microglial activation induced by plasminogen and gangliosides. *Exp Mol Med* 2004; **36**: 461-467 [PMID: 15557818 DOI: 10.1038/emm.2004.58]

27 **Jana M**, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia *via* TLR2: implications for Alzheimer's disease. *J Immunol* 2008; **181**: 7254-7262 [PMID: 18981147 DOI: 10.4049/jimmunol.181.10.7254]

28 **Reed-Geaghan EG**, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. *J Neurosci* 2009; **29**: 11982-11992 [PMID: 19776284 DOI: 10.1523/JNEUROSCI.3158-09.2009]

29 **Stewart CR**, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 Ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. *Nat Immunol* 2010; **11**: 155-161 [PMID: 20037584 DOI: 10.1038/ni.1836]

30 **Chong YH**, Sung JH, Shin SA, Chung JH, Suh YH. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. *J Biol Chem* 2001; **276**: 23511-23517 [PMID: 11306564 DOI: 10.1074/jbc.M009466200]

31 **Park SY**, Park TG, Lee SJ, Bae YS, Ko MJ, Choi YW. α-Iso-cubebenol inhibits inflammation-mediated neurotoxicity and amyloid beta 1-42 fibril-induced microglial activation. *J Pharm Pharmacol* 2014; **66**: 93-105 [PMID: 24138316 DOI: 10.1111/jphp.12160]

32 **Deb S**, Wenjun Zhang J, Gottschall PE. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. *Brain Res* 2003; **970**: 205-213 [PMID: 12706262 DOI: 10.1016/s0006-8993(03)02344-8]

33 **Cao L**, Liu C, Wang F, Wang H. SIRT1 negatively regulates amyloid-beta-induced inflammation *via* the NF-κB pathway. *Braz J Med Biol Res* 2013; **46**: 659-669 [PMID: 24036938 DOI: 10.1590/1414-431X20132903]

34 **Lorenzl S**, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. *Neurochem Int* 2003; **43**: 191-196 [PMID: 12689599 DOI: 10.1016/s0197-0186(03)00004-4]

35 **Ou-Yang MH**, Van Nostrand WE. The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice. *J Neuroinflammation* 2013; **10**: 134 [PMID: 24188129 DOI: 10.1186/1742-2094-10-134]

36 **Heidinger M**, Kolb H, Krell HW, Jochum M, Ries C. Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells. *Biol Chem* 2006; **387**: 69-78 [PMID: 16497166 DOI: 10.1515/BC.2006.010]

**Footnotes**

**Institutional review board statement:** The THP-1 human monocytic cell line was acquired commercially from American Type Culture Collection, thus no human subjects were used in this study.

**Conflict-of-interest statement:** There are no conflicts of interest to declare by any of the authors.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 24, 2020

**First decision:** November 4, 2020

**Article in press:** December 30, 2020

**Specialty type:** Immunology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Exbrayat JM, Rangel-Corona R **S-Editor:** Zhang H **L-Editor: A P-Editor:** Ma YJ


**Figure Legends**




**Figure 1** **Dimethyl sulfoxide inhibits lipopolysaccharide-induced matrix-metalloproteinase-9, but not tumor necrosis factor α, secretion.** THP-1 monocytes were treated in the absence or presence of dimethyl sulfoxide (2%) and with either sterile water or lipopolysaccharide (0.1 μg/mL or 1 μg/mL) for 72 h. A: Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for matrix-metalloproteinase-9 (MMP-9), SDS-PAGE/immunoblot of cell supernatants. Lane 1 is an MMP-9 Western blotting standard (10 μL); B: Densitometry of Panel A. Each data bar is the average ± standard error for three independent densitometry measurements; and C: TNFα levels were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± std error for three independent measurements, Tumor necrosis factor α (TNFα). Statistical differences (a*P* < 0.05 or b*P* < 0.01) for 0.1 μg/mL or 1 μg/mL lipopolysaccharide and dimethyl sulfoxide inhibition of MMP-9 or TNFα secretion are shown. DMSO: Dimethyl sulfoxide; LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.




**Figure 2** **Dimethyl sulfoxide inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 in a dose-dependent fashion.** A: SDS-PAGE/immunoblot of cell supernatants; B: Densitometry of Panel A. Each data bar is the average ± standard error for three independent densitometry measurements. Data were fit to a nonlinear inhibition equation, which produced an IC50 of 0.64%; and C: Tumor necrosis factor α levels were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes were treated with a concentration range of dimethyl sulfoxide (0.1%-1%) followed by lipopolysaccharide (1 μg/mL) for 72 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for (A) matrix-metalloproteinase-9 and (C) tumor necrosis factor α. DMSO: Dimethyl sulfoxide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.




**Figure 3** **Cyclic adenosine monophosphate inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 and tumor necrosis factor α secretion.** A: SDS-PAGE/immunoblot of cell supernatants. Lane 1 is a matrix-metalloproteinase-9 (MMP-9) standard; B: Densitometry of Panel A. Each data bar is the average ± standard error for three independent densitometry measurements; and C: Tumor necrosis factor α (TNFα) levels were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes were treated with 3',5'-cyclic adenosine monophosphate (300 μmol/L) followed by lipopolysaccharide (0.03 μg/mL) for 6, 48, and 72 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for (A) MMP-9 and (C) TNFα. Statistical differences (a*P* < 0.05 or b*P* < 0.01) between MMP-9 secretion at different lipopolysaccharide treatment times and 3',5'-cyclic adenosine monophosphate inhibition of either MMP-9 or TNFα secretion are shown. LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; Bt2-cAMP: 3',5'-cyclic adenosine monophosphate.




**Figure 4** **Activation of adenylyl cyclase inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 and tumor necrosis factor α secretion.** A: SDS-PAGE/immunoblot of cell supernatants. Lane 9 is a matrix-metalloproteinase-9 standard; B: Densitometry of Panel A. Each data bar is the average ± standard error for three independent densitometry measurements; and C: Tumor necrosis factor α (TNFα) levels were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes were treated with three forskolin (Fsk) concentrations that contained different percentages of dimethyl sulfoxide (DMSO), followed by lipopolysaccharide (1 μg/mL) for 72 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for matrix-metalloproteinase-9 and TNFα. The red dashed lines in Panels B and C represent TNFα secretion induced by lipopolysaccharide (1 μg/mL) in the absence of DMSO or Fsk. Statistical differences (a*P* < 0.05 or b*P* < 0.01) between DMSO and DMSO + Fsk are shown. LPS: Lipopolysaccharide; DMSO: Dimethyl sulfoxide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; Fsk: Forskolin.



**Figure 5** **Inhibition of cyclic adenosine monophosphate phosphodiesterase inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 and tumor necrosis factor α in a dose-dependent fashion.** A: SDS-PAGE/WB of cell supernatants; and B: Densitometry of the matrix-metalloproteinase-9 (MMP-9) immunoblot in Panel A (circles). Each data point is the average ± standard error for three independent densitometry measurements. Tumor necrosis factor α (TNFα) levels (diamonds) were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data point is the average ± standard error for three independent measurements. THP-1 monocytes were treated with a concentration range of 3-isobutyl-1-methylxanthine (0.01-0.3 mmol/L) followed by lipopolysaccharide (1 μg/mL) for 48 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for (A) MMP-9 and (B) TNFα. MMP-9 and TNFα data points were fit to a nonlinear inhibition equation, which produced IC50 values of 0.05 mmol/L and 0.08 mmol/L for MMP-9 and TNFα inhibition respectively. LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; IBMX: 3-Isobutyl-1-methylxanthine.



**Figure 6** **Antif- tumor necrosis factor α antibody blocks lipopolysaccharide-induced matrix-metalloproteinase-9 secretion.** THP-1 monocytes were treated with a Tumor necrosis factor α (TNFα) antibody (1 μg/mL) followed by lipopolysaccharide (1 μg/mL) for 48 h. Cells were collected, centrifuged at 500 *g* for 10 min and supernatant assessed for matrix-metalloproteinase-9 and TNFα. A: SDS-PAGE/WB of cell supernatants; and B: Densitometry of Panel A (left plot). Each data bar is the average ± standard error for three independent densitometry measurements. TNFα levels (right plot) were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. Statistical differences (a*P* < 0.05 or b*P* < 0.01) between lipopolysaccharide-stimulated matrix-metalloproteinase-9 or TNFα secretion compared to PBS buffer control and in the absence or presence of an anti-TNFα antibody are shown. LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.



**Figure 7** **Amyloid-β peptide-induced matrix-metalloproteinase-9 secretion occurs much later than tumor necrosis factor α secretion.** THP-1 monocytes were treated with amyloid-β peptide (17 μmol/L) for 6, 24 and 48 h. Cells were collected, centrifuged at 500 *g* for 10 min and supernatant assessed for Matrix-metalloproteinase-9 (MMP-9) and tumor necrosis factor α (TNFα). A: SDS-PAGE/WB of cell supernatants. Lane 1 is an MMP-9 standard; and B: Densitometry of Panel A (left plot). Each data bar is the average ± standard error for three independent densitometry measurements. Enzyme-linked immuno sorbent assay determination of TNFα levels in cell supernatants (right plot). Each data bar is the average ± standard error for three independent measurements. Statistical differences (a*P* < 0.05 or b*P* < 0.01) between MMP-9 or TNFα secretion at different amyloid-β peptide treatment times are shown with an asterisk. Aβ42: Amyloid-β peptide;MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**